Holen Sie sich die Stockscreener-App
42.65
5.43%
-2.32
Schlusskurs vom Vortag:
$44.97
Offen:
$44.31
24-Stunden-Volumen:
684.50K
Relative Volume:
0.31
Marktkapitalisierung:
$5.57B
Einnahmen:
$692.26M
Nettoeinkommen (Verlust:
$-512.41M
KGV:
-10.06
EPS:
-4.24
Netto-Cashflow:
$-274.36M
1W Leistung:
-5.83%
1M Leistung:
-7.75%
6M Leistung:
+104.07%
1J Leistung:
+164.64%
1-Tages-Spanne:
$42.04
$44.97
1-Wochen-Bereich:
$42.04
$46.78
52-Wochen-Spanne:
$16.77
$50.89
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Vergleichen Sie GH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
42.59 | 5.57B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
418.79 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
182.65 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
407.79 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
99.50 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
138.15 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health price target raised to $60 from $56 at BofA - Yahoo Finance
Guardant Health (GH) Price Target Increased by BofA Amid Sector Challenges | GH Stock News - GuruFocus
BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating - marketscreener.com
Lobbying Update: $15,500 of GUARDANT HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Guardant Health to Report First Quarter 2025 Financial Results o - GuruFocus
Circulating Cell-Free Tumor DNA Market Detailed In New Research - openPR.com
S&P 500 Futures Up in Premarket Trading; Guardant Health, Brookfield Wealth Solns Lead - Barron's
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 - The Joplin Globe
Mizuho Initiates Coverage of Guardant Health (GH) with Outperform Recommendation - MSN
Barclays Adjusts Guardant Health (GH) Price Target Amid Sector C - GuruFocus
Mizuho Initiates Guardant Health at Outperform - marketscreener.com
Guardant Health secures facility lease extension through 2031 By Investing.com - Investing.com Canada
‘Preparing For Regulatory Milestones, Commercial Launch’ Are Priorities, Says New Freenome CEO Aaron Elliott - insights.citeline.com
Guardant Health (GH) Receives Outperform Rating from Mizuho with Strong Growth Prospects | GH Stock News - GuruFocus
Guardant Health secures facility lease extension through 2031 - Investing.com
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH) - Yahoo Finance
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Guardant Health partners with Bayshore for cancer tests in Canada By Investing.com - Investing.com South Africa
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada - 01net
Guardant Health partners with Bayshore for cancer tests in Canada - Investing.com
Guardant Health And Bayshore Healthcare Partner To Expand Access To Advanced Precision Oncology Testing In Canada - MarketScreener
A More Convenient Way to Get Screened for Colon Cancer - Sunnyside Sun
(GH) Trading Advice - news.stocktradersdaily.com
4 Healthcare Stocks With Massive Gains—and More to Come - MarketBeat
Guardant Health’s Strategic Growth: Shield’s Coverage Expansion and Revenue Potential - TipRanks
Clinical Applications of ctDNA in Colorectal Cancer: Where Do We Stand? - ASCO Daily News
Liquid Biopsy Market Insights and Projections 2025-2032 - openPR
VA expands coverage to include CRC blood test for veterans By Investing.com - Investing.com Australia
VA expands coverage to include CRC blood test for veterans - Investing.com India
Guardant Health shares rise on VA coverage for cancer test By Investing.com - Investing.com South Africa
Guardant Health shares rise on VA coverage for cancer test - Investing.com
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance
Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa
Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India
1 Healthcare Stock on Our Watchlist and 2 to Turn Down - Yahoo Finance
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360
AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360
Creating awareness for Colorectal Cancer Month - WFLA
Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law News
Guardant Accused of Copying Tempus AI Cancer Research Tech (1) - Bloomberg Law News
Liquid biopsy market flooded with opportunity - BioWorld Online
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):